SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-441697"
 

Search: onr:"swepub:oai:DiVA.org:uu-441697" > Model-Informed Drug...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Rayner, Craig R.Certara, Princeton, NJ 08540 USA; Monash Univ, Monash Inst Pharmaceut Sci, Melbourne, Vic, Australia (author)

Model-Informed Drug Development for Anti-Infectives : State of the Art and Future

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-03-09
  • John Wiley & Sons,2021
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-441697
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-441697URI
  • https://doi.org/10.1002/cpt.2198DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Model-informed drug development (MIDD) has a long and rich history in infectious diseases. This review describes foundational principles of translational anti-infective pharmacology, including choice of appropriate measures of exposure and pharmacodynamic (PD) measures, patient subpopulations, and drug-drug interactions. Examples are presented for state-of-the-art, empiric, mechanistic, interdisciplinary, and real-world evidence MIDD applications in the development of antibacterials (review of minimum inhibitory concentration-based models, mechanism-based pharmacokinetic/PD (PK/PD) models, PK/PD models of resistance, and immune response), antifungals, antivirals, drugs for the treatment of global health infectious diseases, and medical countermeasures. The degree of adoption of MIDD practices across the infectious diseases field is also summarized. The future application of MIDD in infectious diseases will progress along two planes; "depth" and "breadth" of MIDD methods. "MIDD depth" refers to deeper incorporation of the specific pathogen biology and intrinsic and acquired-resistance mechanisms; host factors, such as immunologic response and infection site, to enable deeper interrogation of pharmacological impact on pathogen clearance; clinical outcome and emergence of resistance from a pathogen; and patient and population perspective. In particular, improved early assessment of the emergence of resistance potential will become a greater focus in MIDD, as this is poorly mitigated by current development approaches. "MIDD breadth" refers to greater adoption of model-centered approaches to anti-infective development. Specifically, this means how various MIDD approaches and translational tools can be integrated or connected in a systematic way that supports decision making by key stakeholders (sponsors, regulators, and payers) across the entire development pathway.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Smith, Patrick F.Certara, Princeton, NJ 08540 USA (author)
  • Andes, DavidUniv Wisconsin Madison, Madison, WI USA (author)
  • Andrews, KaylaBill & Melinda Gates Med Res Inst, Cambridge, MA USA (author)
  • Derendorf, HartmutUniv Florida, Gainesville, FL USA (author)
  • Friberg, Lena E.Uppsala universitet,Institutionen för farmaci(Swepub:uu)lenasimo (author)
  • Hanna, DebraBill & Melinda Gates Fdn, Seattle, WA USA (author)
  • Lepak, AlexUniv Wisconsin Madison, Madison, WI USA (author)
  • Mills, EdwardMcMaster Univ, Hamilton, ON, Canada (author)
  • Polasek, Thomas M.Certara, Princeton, NJ 08540 USA; Monash Univ, Ctr Med Use & Safety, Melbourne, Vic, Australia; Royal Adelaide Hosp, Dept Clin Pharmacol, Adelaide, SA, Australia (author)
  • Roberts, Jason A.Univ Queensland, Clin Res Ctr, Fac Med, Brisbane, Qld, Australia; Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia; Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia; Univ Montpellier, Univ Nimes Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Montpellier, France (author)
  • Schuck, VirnaCertara, Princeton, NJ 08540 USA (author)
  • Shelton, Mark J.Certara, Princeton, NJ 08540 USA (author)
  • Wesche, DavidCertara, Princeton, NJ 08540 USA (author)
  • Rowland-Yeo, KarenCertara, Princeton, NJ 08540 USA (author)
  • Certara, Princeton, NJ 08540 USA; Monash Univ, Monash Inst Pharmaceut Sci, Melbourne, Vic, AustraliaCertara, Princeton, NJ 08540 USA (creator_code:org_t)

Related titles

  • In:Clinical Pharmacology and Therapeutics: John Wiley & Sons109:4, s. 867-8910009-92361532-6535

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view